Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Lisa Aniek de Jong, Judith J. Gout-Zwart, Marina van den Bosch, Mike Koops & Maarten J. Postma. (2019) Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. Journal of Medical Economics 22:4, pages 306-318.
Read now
Read now
Joanna B. Eldredge & Alex C. Spyropoulos. (2018) Direct oral anticoagulants in the treatment of pulmonary embolism. Current Medical Research and Opinion 34:1, pages 131-140.
Read now
Read now
Emilie Clay, Aurélien Jamotte, Peter Verhamme, Alexander T. Cohen, Ben. A. Van Hout & Pearl. Gumbs. (2018) Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Christine G. Kohn, Gregory J. Fermann, W. Frank Peacock, Phil S. Wells, Christopher W. Baugh, Veronica Ashton, Concetta Crivera, Jeff R. Schein, Peter Wildgoose & Craig I. Coleman. (2017) Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Current Medical Research and Opinion 33:9, pages 1697-1703.
Read now
Read now
C. Browne, T. Lanitis, M. Hamilton, X. Li, R. Horbyluk, J. Mardekian, T. Kongnakorn & A. Cohen. (2017) Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism. Journal of Medical Economics 20:1, pages 98-106.
Read now
Read now
John Ryan. (2016) Pulmonary embolism: new treatments for an old problem. Open Access Emergency Medicine 8, pages 87-95.
Read now
Read now
Francesco Dentali, Gianluca Di Micco, Matteo Giorgi Pierfranceschi, Gualberto Gussoni, Giovanni Barillari, Maria Amitrano, Andrea Fontanella, Corrado Lodigiani, Anna Guida, Adriana Visonà, Manuel Monreal & Pierpaolo Di Micco. (2015) Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Annals of Medicine 47:7, pages 546-554.
Read now
Read now
Hiroshi Matsuo, Martin Prins, Anthonie W.A. Lensing, Emi Watanabe Fujinuma, Yuki Miyamoto & Mariko Kajikawa. (2015) Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion 31:6, pages 1057-1061.
Read now
Read now
Geno J. Merli, Judd E. Hollander, Patrick Lefebvre, François Laliberté, Monika K. Raut, William H. Olson & Charles V. Pollack$suffix/text()$suffix/text(). (2015) Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Hospital Practice 43:2, pages 85-93.
Read now
Read now
Antonio Gómez-Outes, Mª Luisa Suárez-Gea, Ramón Lecumberri, Ana Isabel Terleira-Fernández & Emilio Vargas-Castrillón. (2014) Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vascular Health and Risk Management 10, pages 627-639.
Read now
Read now
Frank Akwaa & Alex C. Spyropoulos. (2014) The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. Current Medical Research and Opinion 30:11, pages 2179-2190.
Read now
Read now
Brahim K. Bookhart, Lloyd Haskell, Luke Bamber, Maria Wang, Jeff Schein & Samir H. Mody. (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics 17:10, pages 691-695.
Read now
Read now
Samir H. Mody, Lynn Huynh, Daisy Y. Zhuo, Kevin N. Tran, Patrick Lefebvre & Brahim Bookhart. (2014) A cost-analysis model for anticoagulant treatment in the hospital setting. Journal of Medical Economics 17:7, pages 492-498.
Read now
Read now
Articles from other publishers (73)
David P. Ebertz, Saideep Bose, Justin A. Smith, Anuja L. Sarode, Ravi N. Ambani, Jae S. Cho, Norman H. Kumins, Vikram S. Kashyap & Benjamin D. Colvard. (2023) Direct oral anticoagulants over warfarin at discharge associated with improved survival and patency in infra-geniculate bypasses with prosthetic conduits. Journal of Vascular Surgery.
Crossref
Crossref
Rokhsareh Ebrahimi, Mohammad Hasanzadeh, Mohammad-Reza Rashidi & Abolghasem Jouyban. (2023) Low fouling aptasensing of rivaroxaban in real samples using poly (toluidine blue) decorated by silver nanoparticle: A new platform for the cardiovascular disease analysis. Microchemical Journal 189, pages 108529.
Crossref
Crossref
Meixuan Li, Jing Li, Xiaoqin Wang, Xu Hui, Qi Wang, Shitong Xie, Peijing Yan, Jinhui Tian, Jianfeng Li, Ping Xie, Kehu Yang & Liang Yao. (2023) Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2023:4.
Crossref
Crossref
Xiaoqin Wang, Yanfang Ma, Xu Hui, Meixuan Li, Jing Li, Jinhui Tian, Qi Wang, Peijing Yan, Jianfeng Li, Ping Xie, Kehu Yang & Liang Yao. (2023) Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews 2023:4.
Crossref
Crossref
Ayobami S. Ogunsola, Kameron Farhadi, Udeh C. Mercy, Faith Elenwa, Rukayyah M. Karaye, Muhammad Jaafar Baba, Eniola A. Olatunji, Ismaeel Yunusa & Ibraheem M. Karaye. (2023) Analysis of contemporary mortality trends in pulmonary embolism, United States, 1999–2020. Thrombosis Research 223, pages 53-60.
Crossref
Crossref
W. Frank Peacock, Craig Coleman, Phil Wells, Gregory Freeman, Li Wang, Onur Baser, Jeff Schein & Concetta Crivera. (2023) Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research, pages 160-173.
Crossref
Crossref
David P. Ebertz, Saideep Bose, Justin A. Smith, Anuja L. Sarode, Ravi N. Ambani, Jae S. Cho, Norman H. Kumins, Vikram S. Kashyap & Benjamin D. Colvard. (2022) Use of direct-acting oral anticoagulants associated with improved survival and bypass graft patency compared with warfarin after infrageniculate bypass. Journal of Vascular Surgery.
Crossref
Crossref
Prakash Sapkota, Ashish Tamang, Sadikshya Bhandari, Yadvinder Singh, Rohit Bhasink Shrestha, Robin Man Karmacharya, Satish Vaidya & Swechha Bhatt. (2022) Anticoagulation failure in pulmonary thromboembolism in COVID-19 pneumonia despite prolonged anticoagulation: A case series. Annals of Medicine and Surgery 84, pages 104929.
Crossref
Crossref
David Jiménez, Carmen Rodríguez, Beatriz Pintado, Andrea Pérez, Luis Jara-Palomares, Raquel López-Reyes, Pedro Ruiz-Artacho, Alberto García-Ortega, Behnood Bikdeli & José Luis Lobo. (2022) Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Sylvia Haas, Lorenzo G. Mantovani, Reinhold Kreutz, Danja Monje, Jonas Schneider, Elizabeth R. Zell, Miriam Tamm, Martin Gebel, Jörg‐Peter Bugge, Walter Ageno & Alexander G.G. Turpie. (2021) Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies. Research and Practice in Thrombosis and Haemostasis 5:3, pages 426-438.
Crossref
Crossref
Lei Wang, Shuang Jiang, Chao Li, Zhi Xu & Ying Chen. (2021) Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism. Medicine 100:13, pages e25086.
Crossref
Crossref
Nobuhiro Hara, Keita Watanabe, Ryoichi Miyazaki, Tomofumi Nakamura, Tetsumin Lee, Yasutoshi Nagata, Toshihiro Nozato, Takamichi Miyamoto, Toru Obayashi & Takashi Ashikaga. (2020) Administration of Direct Oral Anticoagulant Immediately after Unfractionated Heparin Bolus for the Treatment of Intermediate–High-Risk Pulmonary Thromboembolism. Annals of Vascular Diseases 13:4, pages 370-376.
Crossref
Crossref
Jason Filopei, Eric E. Bondarsky, Madeline Ehrlich, Marjan Islam, Gargi Bajpayee, Daniel Pang, Adil Shujaat, John Rowland & David J. Steiger. (2020) Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience. Journal of Thrombosis and Thrombolysis 50:2, pages 399-407.
Crossref
Crossref
Li Yang & Jingjing Wu. (2020) Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. BMJ Open 10:7, pages e038433.
Crossref
Crossref
Zi‑Kai Song, Hongyan Cao, Haidi Wu, Qi Wei, Minglong Tang, Shuo Yang, Yang Liu & Ling Qin. (2020) Current status of rivaroxaban in elderly patients with pulmonary embolism (Review). Experimental and Therapeutic Medicine.
Crossref
Crossref
Matthias Ebner, Karl-Patrik Kresoja, Karsten Keller, Lukas Hobohm, Nina I. J. Rogge, Gerd Hasenfuß, Burkert Pieske, Stavros V. Konstantinides & Mareike Lankeit. (2019) Temporal trends in management and outcome of pulmonary embolism: a single-centre experience. Clinical Research in Cardiology 109:1, pages 67-77.
Crossref
Crossref
W. Frank Peacock, Craig I. Coleman, Phil Wells, Gregory J. Fermann, Li Wang, Onur Baser, Jeff Schein & Concetta Crivera. (2019) Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. Journal of Health Economics and Outcomes Research 6:3, pages 160-173.
Crossref
Crossref
Murat Sargin, Sevinc Bayer Erdogan, Murat Bastopcu, Gokhan Arslanhan, Muge Mete Tasdemir & Gokcen Orhan. (2019) Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center. Value in Health Regional Issues 19, pages 81-86.
Crossref
Crossref
Ka-Po Fung, Kei-Hong Chan, Vivien Ng, Ping-Tim Tsui & Joyce H. S. You. (2019) Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. Cardiovascular Drugs and Therapy 33:3, pages 331-337.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig Coleman, Gregory Fermann, Jeff Schein & Concetta Crivera. (2019) Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research, pages 84-94.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig I. Coleman, Gregory J. Fermann, Jeff Schein & Concetta Crivera. (2019) Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism. Journal of Health Economics and Outcomes Research 6:2, pages 84-94.
Crossref
Crossref
Lorenzo G. Mantovani, Sylvia Haas, Reinhold Kreutz, Kerstin Folkerts, Martin Gebel, Danja Monje, Jonas Schneider, Martin van Eickels, Kurtulus Sahin, Elizabeth Zell, Walter Ageno & Alexander G.G. Turpie. (2019) Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. European Journal of Internal Medicine 61, pages 29-33.
Crossref
Crossref
Adam D. Porath, Sharon Clodfelter, Terra Slaton, Brahim K. Bookhart, Chris M. Kozma, Michelle L. Rand & Michael J. Bloch. (2019) Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants. Clinical Therapeutics 41:2, pages 269-279.
Crossref
Crossref
Lara M. Groetzinger, Taylor J. Miller, Ryan M. Rivosecchi, Roy E. Smith, Mark T. Gladwin & Belinda N. Rivera-Lebron. (2018) Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis. Clinical and Applied Thrombosis/Hemostasis 24:6, pages 908-913.
Crossref
Crossref
Luke S G E Howard, Steven Barden, Robin Condliffe, Vincent Connolly, Christopher W H Davies, James Donaldson, Bernard Everett, Catherine Free, Daniel Horner, Laura Hunter, Jasvinder Kaler, Catherine Nelson-Piercy, Emma O’Dowd, Raj Patel, Wendy Preston, Karen Sheares & Campbell Tait. (2018) British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax 73:Suppl 2, pages ii1-ii29.
Crossref
Crossref
Yongzhe Hong, Sola Mansour, Ghazi Alotaibi, Cynthia Wu & Michael Sean McMurtry. (2018) Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials. Critical Reviews in Oncology/Hematology 125, pages 12-18.
Crossref
Crossref
Yoshihiro Nakai, Yuko Sumise, Takeshi Yamaguchi & Hiroshi Okamoto. (2018) Direct Oral Anticoagulants for the Treatment of Venous ThromboembolismDOACによる静脈血栓症の治療. The Japanese Journal of Phlebology 29:1, pages 25-31.
Crossref
Crossref
Afsha Aurshina, Pavel Kibrik, Justin Eisenberg, Ahmad Alsheekh, Anil Hingorani, Natalie Marks & Enrico Ascher. (2017) Clinical outcomes of direct oral anticoagulants after lower extremity arterial procedures. Vascular 26:2, pages 189-193.
Crossref
Crossref
Amanda N. Basto, Nathan P. Fewel, Kim Vo, Eileen M. Stock & Mia Ta. (2017) Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. Journal of Thrombosis and Thrombolysis 45:1, pages 51-55.
Crossref
Crossref
Lindsay Robertson, Su Ern Yeoh & Ahmad Ramli. (2017) Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database of Systematic Reviews 2017:12.
Crossref
Crossref
Catherine A Saint, Michelle R Castelli, Andrew J Crannage, Zachary A Stacy & Erin K Hennessey. (2017) Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Medicine 5, pages 205031211771962.
Crossref
Crossref
Craig I. Coleman, Gregory J. Fermann, Erin R. Weeda, Philip S. Wells, Veronica Ashton, Concetta Crivera, Thomas J. Bunz, Peter Wildgoose, Jeff R. Schein & W. Frank Peacock. (2016) Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?. Clinical and Applied Thrombosis/Hemostasis 23:7, pages 830-837.
Crossref
Crossref
Petros Ioannou, Emmanouela Tsagkaraki, Aggeliki M. Andrianaki & John A. Papadakis. (2017) Unnecessary hospitalizations for DVT in the era of NOACs. European Journal of Internal Medicine 44, pages e40-e41.
Crossref
Crossref
George Gourzoulidis, Georgia Kourlaba, John Kakisis, Mitiadis Matsagkas, George Giannakoulas, Konstantinos I. Gourgoulianis, Theodoros Vassilakopoulos & Nikos Maniadakis. (2017) Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clinical Drug Investigation 37:9, pages 833-844.
Crossref
Crossref
Luca Masotti, Vieri Vannucchi, Marzia Poggi & Giancarlo Landini. (2017) Trends in length of hospital stay in acute pulmonary embolism over the years. What is changing in the era of direct oral anticoagulants?. Journal of Cardiovascular Medicine 18:7, pages 556-559.
Crossref
Crossref
Li Wang, Onur Baser, Phil Wells, W. Frank Peacock, Craig I. Coleman, Gregory J. Fermann, Jeff Schein & Concetta Crivera. (2017) Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clinical Therapeutics 39:7, pages 1426-1436.e2.
Crossref
Crossref
Luis Miguel Salmerón Febres & Jorge Cuenca Manteca. (2017) Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease. Annals of Vascular Surgery 42, pages 337-350.
Crossref
Crossref
Yi-Min Zhang, Xin Jiang & Yan-Shan Sun. (2017) Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement. Bioscience Reports 37:3.
Crossref
Crossref
Torben B Larsen, Flemming Skjøth, Jette N Kjældgaard, Gregory Y H Lip, Peter B Nielsen & Mette Søgaard. (2017) Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. The Lancet Haematology 4:5, pages e237-e244.
Crossref
Crossref
Franco Piovella & Diana I. Iosub. (2017) Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism. Thrombosis Research 152, pages 87-92.
Crossref
Crossref
Erin R. Weeda, Philip S. Wells, W. Frank Peacock, Gregory J. Fermann, Christopher W. Baugh, Veronica Ashton, Concetta Crivera, Peter Wildgoose, Jeff R. Schein & Craig I. Coleman. (2016) Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Internal and Emergency Medicine 12:3, pages 311-318.
Crossref
Crossref
Tammy J. Bungard & William Semchuk. (2017) The management of venous thromboembolism. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 150:2, pages 81-89.
Crossref
Crossref
Rupert Bauersachs & Norimichi Koitabashi. (2017) Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism. International Heart Journal 58:1, pages 6-15.
Crossref
Crossref
Erin R. Weeda, W. Frank Peacock, Gregory J. Fermann, Christopher W. Baugh, Philip S. Wells, Veronica Ashton, Concetta Crivera, Peter Wildgoose, Jeff R. Schein & Craig I. Coleman. (2017) Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. International Journal of Clinical Practice 71:1, pages e12915.
Crossref
Crossref
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Concetta Crivera, Brahim Bookhart & Jeff Schein. (2016) Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. Clinical Therapeutics 38:11, pages 2496-2503.
Crossref
Crossref
J. Stevanović, L. A. de Jong, B. S. Kappelhoff, E. P. Dvortsin, M. Voorhaar & M. J. Postma. (2016) Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PLOS ONE 11:10, pages e0163550.
Crossref
Crossref
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Brahim Bookhart, Concetta Crivera & Jeff Schein. (2016) Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. Journal of the American Heart Association 5:10.
Crossref
Crossref
Erin R. Weeda, Christine G. Kohn, W. Frank Peacock, Gregory J. Fermann, Concetta Crivera, Jeff R. Schein & Craig I. Coleman. (2016) Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:10, pages 1109-1115.
Crossref
Crossref
Franco Piovella & Diana Irina Iosub. (2015) Acute pulmonary embolism: risk assessment, risk stratification and treatment options. The Clinical Respiratory Journal 10:5, pages 545-554.
Crossref
Crossref
Raquel Morillo, David Jiménez, Miguel Ángel Aibar, Daniela Mastroiacovo, Philip S. Wells, Ángel Sampériz, Marta Saraiva de Sousa, Alfonso Muriel, Roger D. Yusen, Manuel Monreal, Manuel Monreal, Hervè Decousus, Paolo Prandoni, Benjamin Brenner, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Henri Bounameaux, Radovan Malý, Philip Wells, Manolis Papadakis, P. Agudo, M.A. Aibar, M. Akasbi, M. Alcalde-Manero, V. Andújar, J.I. Arcelus, A. Ballaz, R. Barba, M. Barrón, B. Barrón-Andrés, J. Bascuñana, A. Blanco-Molina, I. Cañas, I. Casado, J. de Miguel, J. del Toro, S. Díaz, J.A. Díaz-Peromingo, C. Falgá, C. Fernández-Capitán, C. Font, L. Font, P. Gallego, F. García-Bragado, M. García-Rodenas, V. Gómez, C.J. González, E. Grau, L. Guirado, J. Gutiérrez, G. Hernández, L. Hernández-Blasco, V. Isern, L. Jara-Palomares, M.J. Jaras, D. Jiménez, J.L. Lobo, L. López-Jiménez, R. López-Reyes, J.B. López-Sáez, M.A. Lorente, A. Lorenzo, O. Madridano, A. Maestre, P.J. Marchena, M. Martín, J.M. Martín-Antorán, F. Martín-Martos, M. Monreal, M.V. Morales, D. Nauffal, J.A. Nieto, S. Nieto, M.J. Núñez, C. Orbegoso, S. Otalora, R. Otero, B. Pagán, J.M. Pedrajas, C. Pérez, G. Pérez, M.L. Peris, I. Pons, J.A. Porras, O. Reig, A. Riera-Mestre, A. Rivas, C. Rodríguez, M.A. Rodríguez-Dávila, V. Rosa, A.S. Rosa-Murillo, N. Ruiz-Giménez, J.C. Sahuquillo, M.C. Sala, A. Sampériz, R. Sánchez, O. Sanz, S. Soler, J.M. Suriñach, C. Tolosa, J. Trujillo-Santos, F. Uresandi, B. Valero, R. Valle, J. Vela, G. Vidal, C. Vilar, J. Villalta, B. Xifre, T. Vanassche, P. Verhamme, P. Wells, J. Hirmerova, R. Malý, T. Tomko, G. Celis, E. Salgado, G.T. Sánchez, L. Bertoletti, A. Bura-Riviere, D. Farge-Bancel, A. Hij, I. Mahé, A. Merah, I. Quere, M. Papadakis, A. Braester, B. Brenner, I. Tzoran, A. Apollonio, G. Barillari, A. Bertone, F. Bilora, E. Bucherini, M. Ciammaichella, P. De Ciantis, F. Dentali, P. Di Micco, R. Duce, P. Ferrazzi, E. Grandone, G. Lessiani, C. Lodigiani, D. Mastroiacovo, F. Pace, R. Pesavento, M. Pinelli, R. Poggio, P. Prandoni, M. Rosa, L. Rota, E. Tiraferri, D. Tonello, A. Tufano, U. Venturelli, A. Visonà, B. Zalunardo, E. Drucka, D. Kigitovica, A. Skride, A. Mafalda, J.L. Ribeiro, M.S. Sousa, M. Bosevski, M. Zdraveska, H. Bounameaux & L. Mazzolai. (2016) DVT Management and Outcome Trends, 2001 to 2014. CHEST 150:2, pages 374-383.
Crossref
Crossref
Anish Desai, Amishi Desai, Rose Calixte, Malaygiri Aparnath, Alexander Hindenburg, Steve Salzman & Joseph P. Mathew. (2016) Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Lung 194:4, pages 605-611.
Crossref
Crossref
R.M. Bauersachs, S. Haas, R. Kreutz, M. Gebel, J. Herold, J. Schneider, P. Weyrauch & J. Beyer-Westendorf. (2017) Safety and effectiveness of rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis in routine clinical practice. Phlebologie 45:04, pages 187-193.
Crossref
Crossref
Serena Granziera, Arjumand Hasan & Alexander (Ander) T. Cohen. (2015) Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis 22:3, pages 209-221.
Crossref
Crossref
Cecilia Becattini & Giancarlo Agnelli. (2016) Treatment of Venous Thromboembolism With New Anticoagulant Agents. Journal of the American College of Cardiology 67:16, pages 1941-1955.
Crossref
Crossref
William Frank Peacock, Phillip D. Levy, Michael G. Gonzalez & Martin Than. (2016) Target-specific Oral Anticoagulants in the Emergency Department. The Journal of Emergency Medicine 50:2, pages 246-257.
Crossref
Crossref
Brit J. Long & Alex Koyfman. (2016) Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death?. Annals of Emergency Medicine 67:2, pages 260-262.
Crossref
Crossref
I. V. Schastlivtsev, K. V. Lobastov, V. E. Barinov, A. V. Vorontsova, S. V. Tsaplin, I. V. Barinova & V. V. Boyarintsev. (2016) The Effectiveness and the Safety of Rivaroxaban in Comparison with Vitamin K Antagonists During the Long-Term Treatment of Venous Thrombosis. Flebologiia 10:1, pages 19.
Crossref
Crossref
Walter Ageno & Alexander Turpie. (2017) Spotlight on real-world evidence for the treatment of DVT: XALIA. Thrombosis and Haemostasis 116:S 02, pages S41-S49.
Crossref
Crossref
Jan Beyer-Westendorf, A. Camm, Craig Coleman & CAPT Tamayo. (2017) Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. Thrombosis and Haemostasis 116:S 02, pages S13-S23.
Crossref
Crossref
Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Elizabeth Zell & Alexander G G Turpie. (2016) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology 3:1, pages e12-e21.
Crossref
Crossref
Peter Manu, Christopher Hohman, James F. Barrecchia & Matisyahu Shulman. 2016. Life-Threatening Effects of Antipsychotic Drugs. Life-Threatening Effects of Antipsychotic Drugs
59
79
.
Kirsten M. Roberts, Tamara B. Knight, Eimeira Padilla-Tolentino, Manasa Murthy & Evan J. Peterson. (2015) Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study. Thrombosis 2015, pages 1-6.
Crossref
Crossref
Lindsay Robertson, Patrick Kesteven & James E McCaslin. (2015) Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews 2016:12.
Crossref
Crossref
Luke Bamber, Dominic Muston, Euan McLeod, Anne Guillermin, Julia Lowin & Raj Patel. (2015) Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thrombosis Journal 13:1.
Crossref
Crossref
Lindsay Hom & Diana M. Sobieraj. (2015) The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism. International Journal of Cardiology 198, pages 87-88.
Crossref
Crossref
David Jiménez, Sònia Jiménez, Iciar Martínez-López, Manuel Monreal, Vicente Vicente, Ferran Pérez-Alcántara, Ruth Graefenhain & Ana Vieta. (2015) Análisis coste-efectividad de rivaroxabán en el tratamiento del tromboembolismo venoso en España. PharmacoEconomics Spanish Research Articles 12:4, pages 147-156.
Crossref
Crossref
Christine G. Kohn, Elizabeth S. Mearns, Matthew W. Parker, Adrian V. Hernandez & Craig I. Coleman. (2015) Prognostic Accuracy of Clinical Prediction Rules for Early Post-Pulmonary Embolism All-Cause Mortality. Chest 147:4, pages 1043-1062.
Crossref
Crossref
Jan Beyer-Westendorf & Walter Ageno. (2017) Benefit–risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thrombosis and Haemostasis 113:02, pages 231-246.
Crossref
Crossref
Paolo Prandoni, Martin H. Prins, Alexander T. Cohen, Katharina Müller, Ákos F. Pap, Miriam C. Tewes & Anthonie W. A. Lensing. (2015)
Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the
EINSTEIN DVT
and
EINSTEIN PE
Studies
. Academic Emergency Medicine 22:2, pages 142-149.
Crossref
Crossref
Joseph F. Dasta, Dominic Pilon, Samir H. Mody, Jessica Lopatto, François Laliberté, Guillaume Germain, Brahim K. Bookhart, Patrick Lefebvre & Edith A. Nutescu. (2015) Daily Hospitalization Costs in Patients with Deep Vein Thrombosis or Pulmonary Embolism Treated with Anticoagulant Therapy. Thrombosis Research 135:2, pages 303-310.
Crossref
Crossref
Martin H. Prins, Luke Bamber, Stefan J. Cano, Maria Y. Wang, Petra Erkens, Rupert Bauersachs & Anthonie W.A. Lensing. (2015) Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research 135:2, pages 281-288.
Crossref
Crossref
Marlene Robinson. (2015) Non-Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care. Open Journal of Nursing 05:12, pages 1142-1157.
Crossref
Crossref
Tuyet-Trinh N. Truong, Daniel S. Jones & Andrew S. Dunn. (2014) Pulmonary Embolism. Hospital Medicine Clinics 3:4, pages 479-493.
Crossref
Crossref